Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
Sacha Gnjatic(Mount Sinai Hospital), Lisa H. Butterfield(UPMC Hillman Cancer Center), John M. Kirkwood(UPMC Hillman Cancer Center), Marcus O. Butler(University of Toronto), Dolores J. Schendel(Medigene (Germany)), Isabelle Tanneau, Vaios Karanikas(Roche (Switzerland)), Lance D. Miller(Genome Institute of Singapore), Laura Rosa Brunet(Immodulon Therapeutics (United Kingdom)), Samir N. Khleif(Georgetown University), Mary L. Disis(University of Washington), Jon M. Wigginton(Johns Hopkins University), Vincenzo Bronte(Istituti di Ricovero e Cura a Carattere Scientifico), Leif Håkansson(Lund University), Jérôme Galon(Inserm), Brent A. Hanks(University of North Carolina at Chapel Hill)
Cited by 239
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
|Immunity|2013|4.7k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k